Valeritas Holdings, Inc. to held a conference call regarding revenue for V-Go® Wearable Insulin Delivery device

Valeritas Holdings, Inc. announced last May 1st that it would release its financial results for the first-quarter of 2018 after the close of trading on Wednesday. The Company’s management team will host a corresponding conference call beginning at 4:30 PM ET to discuss the financial results and recent business developments.

Valeritas Holdings, Inc. is a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots.

AMCP Managed Care and Specialty Pharmacy Annual Meeting held in Boston published positive findings from a new study during the poster presentations.

The findings from the ENABLE (Effectiveness of V-Go Wearable Insulin Delivery for Basal-Bolus Therapy) study, demonstrated that patients who switched to V-Go from insulin pens or syringes experienced a more significant reduction in A1C levels and insulin total daily dose (TDD).

“Insulin only works if patients take it and the current standard of asking patients to inject themselves multiple times a day has its challenges,” said John Timberlake, President and Chief Executive Officer of Valeritas.

“We believe V-Go provides patients a simple and convenient way to deliver basal-bolus insulin and the findings from this new study continue to support the use of V-Go for insulin delivery results in better glucose control,” he added.

An insulin patch aims to painlessly deliver insulin through the skin similar to how transdermal patches such as nicotine patches or muscle pain relief patches work. An insulin patch works by being placed on the surface and agents within the patch help insulin to pass through the skin and then into the bloodstream. An insulin patch contains a set dose of insulin that is absorbed over some hours.

The V-Go concentrates on two types of therapy. One is basal insulin patches, which quickly counteracts rises in blood sugar following meals, and the other is bolus insulin patches, to fight-off the gradual release of glucose through the day by the liver.